|View printer-friendly version|
|November 21, 2002 4:26 p.m.|
|Teva Announces Potential Neuroprotection Properties of Copaxone® discovered by Researchers|
New Evidence Shows Drug could Protect Patients From Neuronal Loss
Jerusalem, Israel, November 21, 2002 - Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA) announced today that European researchers have uncovered new evidence that COPAXONE® (glatiramer acetate for injection) not only reduces relapse rate in relapsing-remitting multiple sclerosis (MS) but also encourages the release of a factor that helps protect the brain from axonal loss.